In general, the mutational frequency data combined with the observation from the simulations suggest that at least in the pancreatic cancer, where a KRAS mutation is a key initiator [68], a major shift in KRAS dynamics is not tolerated. This evidence concerns the gene KRAS and pancreatic neoplasm.